Opinion|Videos|August 28, 2024
Understanding Financial Toxicity in Myelofibrosis
Addressing financial toxicity associated with myelofibrosis treatment, Dr Mahmoudjafari discusses cost considerations and how lower WAC products can benefit patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- From a patient perspective, what are some financial toxicity considerations that should be considered, particularly for those patients with co-insurance or high deductible health plan pharmacy benefit design?
- For patients enrolled in high deductible health plans, how do lower WAC products affect their out-of-pocket expenses?
- For patients enrolled in high deductible health plans, how do lower WAC products affect their out-of-pocket expenses?
Advertisement
Related to this article
"Payviders" are responsible for the cost of avoidable readmissions and emergency room visits, but they lose sight of patients once they go home.
Jenny Goins, interim head of the National Alliance of Healthcare Purchaser Coalitions, says employers need the same visibility into medical benefits that a new Department of Labor rule gives them into PBM compensation.
Only 19% of community oncologists use AI predictive models. Prerna Mewawalla, M.D., outlines six ways AI can already help in myeloma care.
Jamilia Sherls, DNP, says health systems should track vaccine coverage closely and look to AAP schedules if federal guidance isn't evidence-based.
Model N's Jesse Mendelsohn explains why drug manufacturers argued that a 340B rebates instead of upfront discounts will avoid an overlapping maximum fair price and 340B discounts
People with ADHD had a 70% higher risk of death from any cause in a 19-study meta-analysis, with excess deaths from suicide, injury and natural causes.
Bronchiectasis affected 221.6 per 100,000 people in the U.S. over five years, which is higher than earlier national estimates, according to a study published in CHEST.
Cepheid’s Xpert Respiratory Panel, which tests one swab for nine viruses and four bacteria, is now certified for sale in Europe under the IVDR.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The payvider blind spot: When clinical visibility ends but financial risk continues
2
Quick Q&A: Jenny Goins on bringing PBM-style transparency to the medical side of benefits
3
Bronchiectasis is more common in the U.S. than a decade ago, study finds
4
Six jobs for AI in myeloma care, from Prerna Mewawalla, M.D.
5